Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction

被引:31
作者
Nijland, Esme
Davis, Susan
Laan, Ellen
Schultz, Willibrord Weijmar
机构
[1] NV Organon, Med Serv Womens Hlth, Urol, NL-5340 BH Oss, Netherlands
[2] Monash Univ, Alfred Hosp, Womens Hlth Program, Clayton, Vic 3168, Australia
[3] Univ Amsterdam, Acad Med Ctr, Dept Sexol & Psychosomat Obstet Gynecol, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Groningen Hosp, Dept Gynecol, Groningen, Netherlands
关键词
female sexual dysfunction; menopause; hormones; estrogens; testosterone; sildenafil; DHEAS; androgens;
D O I
10.1111/j.1743-6109.2006.00285.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. A considerable number of double-blind randomized controlled studies investigating the effects of pharmaceutical intervention on female sexual functioning have been published in recent years. However, a comparison between outcomes of various studies is difficult as no generally accepted/correct approach to research has been established yet. To be able to translate trial results to daily clinical practice, current limitations and issues in drug intervention studies in female sexual dysfunction (FSD) need to be clarified. Aim. To evaluate the needs in research into intervention in FSD by reviewing published studies. Methods. A systematic review of double-blind randomized controlled intervention trials on FSD. Main Outcome Measures. Definitions of study populations, inclusion and exclusion criteria, use of power calculations, outcome measures and treatment duration. Results. A total of 25 double-blind randomized controlled trials investigating the effects of pharmaceutical intervention on female sexual functioning have been published. Of these, 11 studies required the diagnosis of FSD as an inclusion criterion. A standard methodology for research in this field is lacking. Significant differences in population inclusion requirements and tools for the measurement of change in sexual functioning were identified as major limiting factors. Conclusions. The investigation of FSD is an evolving area in that new definitions and a new model for female sexual functioning have been recently proposed. There is a need for experts in the field and regulating authorities to reach a consensus regarding appropriate inclusion and exclusion criteria for FSD trials and main outcome measures appropriate for the evaluation of drug interventions. This consensus should also determine which treatment effect is considered to be clinically relevant. Treatment efficacy and clinical relevance should be related to outcomes which are meaningful for affected women.
引用
收藏
页码:763 / 777
页数:15
相关论文
共 50 条
  • [41] Female Sexual Dysfunction in Primary Adrenal Insufficiency
    Zamponi, Virginia
    Lardo, Pina
    Maggio, Roberta
    Simonini, Chiara
    Mazzilli, Rossella
    Faggiano, Antongiulio
    Pugliese, Giuseppe
    Stigliano, Antonio
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [42] History of the Treatment of Female Sexual Dysfunction (s)
    Kleinplatz, Peggy J.
    [J]. ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 14, 2018, 14 : 29 - 54
  • [43] Therapy of female sexual dysfunction in multiple sclerosis
    Lew-Starowicz, Michal
    Rola, Rafal
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (02): : 166 - 174
  • [44] The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response
    Billups, KL
    [J]. WORLD JOURNAL OF UROLOGY, 2002, 20 (02) : 137 - 141
  • [45] Obesity and sexual dysfunction, male and female
    Esposito, K.
    Giugliano, F.
    Ciotola, M.
    De Sio, M.
    D'Armiento, M.
    Giugliano, D.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2008, 20 (04) : 358 - 365
  • [46] Female sexual dysfunction: are urogynecologists ready for it?
    Anne-Marie Roos
    Ranee Thakar
    Abdul H. Sultan
    Inka Scheer
    [J]. International Urogynecology Journal, 2009, 20 : 89 - 101
  • [47] Vascular testing in female sexual dysfunction
    John P. Mulhall
    [J]. Current Sexual Health Reports, 2004, 1 (1) : 12 - 16
  • [48] Future Targets for Female Sexual Dysfunction
    Farmer, Melissa
    Yoon, Hana
    Goldstein, Irwin
    [J]. JOURNAL OF SEXUAL MEDICINE, 2016, 13 (08) : 1147 - 1165
  • [49] Physiology of female sexual function and dysfunction
    Berman, JR
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (Suppl 1) : S44 - S51
  • [50] Management of Hypertension with Female Sexual Dysfunction
    Zhong, Qing
    Anderson, Yuri
    [J]. MEDICINA-LITHUANIA, 2022, 58 (05):